BRAF and melanoma: Since PK2M activity and aerobic glycolysis are upregulated in BRAF inhibitors resistant melanoma cells, treatment with benserazide results in a heightened sensitivity to suppressed PK2M expression both in vitro and in vivo, with potential therapeutic applications [210].